HUP0300627A2 - Terápiára alkalmas szintetikus oligonukleotidok - Google Patents

Terápiára alkalmas szintetikus oligonukleotidok

Info

Publication number
HUP0300627A2
HUP0300627A2 HU0300627A HUP0300627A HUP0300627A2 HU P0300627 A2 HUP0300627 A2 HU P0300627A2 HU 0300627 A HU0300627 A HU 0300627A HU P0300627 A HUP0300627 A HU P0300627A HU P0300627 A2 HUP0300627 A2 HU P0300627A2
Authority
HU
Hungary
Prior art keywords
synthetic oligonucleotides
gxty
tygx
therapeutically useful
useful synthetic
Prior art date
Application number
HU0300627A
Other languages
English (en)
Inventor
Mario C. Filion
Nigel C. Phillips
Original Assignee
Bioniche Life Sciences Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Life Sciences Inc. filed Critical Bioniche Life Sciences Inc.
Publication of HUP0300627A2 publication Critical patent/HUP0300627A2/hu
Publication of HUP0300627A3 publication Critical patent/HUP0300627A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány tárgyát 2--20 bázis méretű 3'-OH, 5'-OH szintetikusoligonukleotidokat (szekvenciákat) tartalmazó készítmények éseljárások képezik, amelyekben a szintetikus oligonukleotidok lehetnek(GxTy)n (I), (TyGx) n (II), a (GxTy)n, (III), (GxTy)nb (IV), (TyGx)nb(V), a(GxTy)nb (VI), a(TyGx)nb (VII) összetételűek, ahol a képletekbenx és y értéke 1-7, bármely egész szám, n értéke 1-12. bármely egészszám, továbbá a és b jelentése egy vagy több A, C, G vagy T, és amelyszekvenciák a sejtciklus megállítását, sejtosztódás gátlását,kaszpázok aktiválását, rákos sejtekben az apoptózist vagy azimmunrendszer sejtjeiben citokinek előállítását indukálják. Ó
HU0300627A 1999-12-13 2000-12-12 Therapeutically useful synthetic oligonucleotides HUP0300627A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17032599P 1999-12-13 1999-12-13
US22892500P 2000-08-29 2000-08-29
PCT/CA2000/001467 WO2001044465A2 (en) 1999-12-13 2000-12-12 Therapeutically useful synthetic oligonucleotides

Publications (2)

Publication Number Publication Date
HUP0300627A2 true HUP0300627A2 (hu) 2004-06-28
HUP0300627A3 HUP0300627A3 (en) 2005-11-28

Family

ID=26865979

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300627A HUP0300627A3 (en) 1999-12-13 2000-12-12 Therapeutically useful synthetic oligonucleotides

Country Status (18)

Country Link
US (2) US7157436B2 (hu)
EP (2) EP1238070B1 (hu)
JP (1) JP4772245B2 (hu)
KR (1) KR100829646B1 (hu)
CN (2) CN100445380C (hu)
AT (2) ATE455851T1 (hu)
AU (1) AU785212B2 (hu)
CA (1) CA2393808A1 (hu)
CZ (1) CZ20022372A3 (hu)
DE (2) DE60036019T2 (hu)
DK (2) DK1238070T3 (hu)
ES (2) ES2288883T3 (hu)
HU (1) HUP0300627A3 (hu)
IL (2) IL150196A0 (hu)
MX (1) MXPA02005842A (hu)
NO (1) NO330508B1 (hu)
PT (1) PT1238070E (hu)
WO (1) WO2001044465A2 (hu)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032610A1 (en) 1996-06-03 2003-02-13 Gilchrest Barbara A. Method to inhibit cell growth using oligonucleotides
PT1181304E (pt) 1999-04-08 2008-01-23 Antisoma Res Ltd Actividade antiproliferativa de oligonucleótidos ricos em g e método de utilização dos mesmos para ligação a nucleolina
US7960540B2 (en) 1999-04-08 2011-06-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US8114850B2 (en) 1999-04-08 2012-02-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
CN100445380C (zh) * 1999-12-13 2008-12-24 拜昂尼科生命科学有限公司 治疗用合成寡核苷酸
AU6886301A (en) 2000-08-29 2002-03-13 Bioniche Life Sciences Inc Modulation of fas and fasl expression
ES2307568T3 (es) * 2000-12-08 2008-12-01 Coley Pharmaceutical Gmbh Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
US7087586B2 (en) * 2001-04-24 2006-08-08 Bioniche Life Sciences, Inc. Oligonucleotide compositions and their use to induce differentiation of cells
EP1417307B1 (en) * 2001-08-17 2009-04-15 Bioniche Life Sciences Inc. Oligonucleotide compositions and their use to induce apoptosis
EP1432450B1 (en) * 2001-10-03 2005-12-28 Bioniche Life Sciences Inc. Therapeutically useful triethyleneglycol cholesteryl oligonucleotides
AU2003219383B2 (en) * 2002-04-22 2010-08-26 Bioniche Life Sciences Inc. Oligonucleotide compositions and their use for the modulation of immune responses
WO2004087203A2 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
US7569554B2 (en) * 2003-05-16 2009-08-04 Idera Pharmaceuticals, Inc. Synergistic treatment of cancer using immunomers in conjunction with therapeutic agents
CA2598992A1 (en) * 2005-02-24 2006-08-31 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
EP1863538A4 (en) * 2005-03-09 2009-01-14 Baylor College Medicine DIRECT INVERSION OF CD4 + T CELL LYMPHOCYTE INHIBITOR FUNCTION VIA TOLL-TYPE 8 RECEIVER SIGNALING
GB2443591B (en) * 2005-09-07 2010-04-28 Secr Defence Adjuvanted vaccine
ES2658626T3 (es) * 2009-02-12 2018-03-12 Curna, Inc. Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de células gliales (GDNF) por inhibición de transcrito antisentido natural a GDNF
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
KR100998365B1 (ko) 2009-06-29 2010-12-06 압타바이오 주식회사 치료 효능이 있는 변형핵산 및 구아노신을 함유하는 올리고뉴클레오티드 변형체
TW201102073A (en) * 2009-07-15 2011-01-16 Enzon Pharmaceuticals Inc RNA antagonists targeting GLI2 for the treatment of leukemia
WO2013129603A1 (ja) * 2012-02-28 2013-09-06 国立大学法人東京農工大学 Tdp-43細胞内存在量関連疾患の認定方法
EP4000597A1 (en) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptide and compositions comprising tetrapeptides
CA3242118A1 (en) * 2021-12-22 2023-06-29 Alfica Sehgal Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172815A (en) * 1962-04-24 1965-03-09 Warner Lambert Pharmaceutical Method for preparing reticulo-endo-thelial system stimulant and stimulant thereof
US4152423A (en) * 1971-11-19 1979-05-01 Agence Nationale De Valorisation De La Recherche (Anvar) Immunological agents
FR2160326B1 (hu) * 1971-11-19 1975-02-07 Anvar
CH602920A5 (hu) * 1973-02-23 1978-08-15 Wellcome Found
US3976544A (en) * 1973-06-19 1976-08-24 The Agence Nationale De Valorisation De Le Recherche Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction
FR2374042A1 (fr) * 1976-06-04 1978-07-13 Merieux Inst Nouveau medicament immunostimulant et son procede de preparation
JPS54140710A (en) * 1978-03-10 1979-11-01 Mitsui Toatsu Chem Inc Anti-tumor substance and its preparation
DE3011461C2 (de) * 1980-03-25 1986-10-30 Dr. Madaus & Co, 5000 Köln Verwendung von Propionibakterien
US4520019A (en) * 1982-04-29 1985-05-28 Ribi Immunochem Research, Inc. Stable composition and preparation thereof
US4579941A (en) * 1982-08-13 1986-04-01 Mitsuitoatsu Chemicals, Inc. Thermally-denatured deoxyribonucleic acid MD-011 and antitumor agent
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
US4744984A (en) * 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
DE3723075A1 (de) * 1987-07-11 1989-01-19 Boehringer Mannheim Gmbh Eukaryotische expressionsvektoren mit multimeren enhancer-subelementen, verfahren zu ihrer herstellung und verwendung
US4958013A (en) * 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
WO1992007095A1 (en) * 1990-10-15 1992-04-30 Stratagene Arbitrarily primed polymerase chain reaction method for fingerprinting genomes
AU1456092A (en) * 1991-02-21 1992-09-15 Gilead Sciences, Inc. Aptamers specific for thrombin and methods of use
CA2268476A1 (en) * 1991-07-03 1998-04-30 Hyal Pharmaceutical Corporation Use of hyaluronan in gene therapy
US5582981A (en) * 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US5523389A (en) * 1992-09-29 1996-06-04 Isis Pharmaceuticals, Inc. Inhibitors of human immunodeficiency virus
ATE179333T1 (de) * 1993-01-29 1999-05-15 Vetrepharm Inc Immunotherapeutische zubereitung
US5567604A (en) * 1993-04-23 1996-10-22 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides
CN1154702A (zh) * 1994-05-25 1997-07-16 海布里登公司 具有抗巨细胞病毒活性的寡核苷酸
US6211431B1 (en) * 1994-08-30 2001-04-03 Commonwealth Scientific And Industrial Research Organization Plant transcription regulators from circovirus
US5643890A (en) * 1995-01-31 1997-07-01 The Board Of Regents Of The University Of Nebraska Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
IN181358B (hu) * 1995-02-14 1998-05-30 Bioniche Inc
ZA964446B (en) * 1995-06-06 1996-12-06 Hoffmann La Roche Oligonucleotides specific for hepatitis c virus
US5990299A (en) * 1995-08-14 1999-11-23 Icn Pharmaceuticals, Inc. Control of CD44 gene expression for therapeutic use
EA000841B1 (ru) * 1995-11-21 2000-04-24 Ай-Си-Эн ФАРМАСЬЮТИКАЛЗ Антисмысловые олигонуклеотиды к ил-8 и рецептору ил-8 и способ лечения злокачественных опухолей
IT1277025B1 (it) * 1995-12-04 1997-11-04 Cooperativa Centro Ricerche Po Classe di oligonucleotidi fosfodiesterici ad attivita' citotossica composizioni farmaceutiche che li contengono e loro uso
US6015710A (en) * 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
ATE383172T1 (de) * 1996-05-20 2008-01-15 Us Gov Health & Human Serv Oligonukleotide welche spezifisch retrovirale nukleokapsid-proteine binden
KR100533576B1 (ko) * 1997-08-05 2005-12-05 바이오니취 라이프 사이언시즈 인코포레이티드 세포증식 및 세포사멸 조절용 조성물 및 방법
US6255473B1 (en) * 1997-08-29 2001-07-03 Duke University Presenilin-1 gene promoter
DK1221955T3 (da) * 1999-09-25 2006-01-30 Univ Iowa Res Found Immunstimulerende nukleinsyre
CN100445380C (zh) * 1999-12-13 2008-12-24 拜昂尼科生命科学有限公司 治疗用合成寡核苷酸
US20020091095A1 (en) * 1999-12-13 2002-07-11 Phillips Nigel C. Modulation of Fas and FasL expression
AU784356B2 (en) * 1999-12-28 2006-03-16 Bioniche Urology Ip Inc. Hyaluronic acid in the treatment of cancer
EP1432450B1 (en) * 2001-10-03 2005-12-28 Bioniche Life Sciences Inc. Therapeutically useful triethyleneglycol cholesteryl oligonucleotides
AU2003219383B2 (en) * 2002-04-22 2010-08-26 Bioniche Life Sciences Inc. Oligonucleotide compositions and their use for the modulation of immune responses

Also Published As

Publication number Publication date
EP1238070A2 (en) 2002-09-11
WO2001044465A2 (en) 2001-06-21
EP1867718A3 (en) 2008-04-02
DE60036019T2 (de) 2008-05-29
HUP0300627A3 (en) 2005-11-28
ES2288883T3 (es) 2008-02-01
CA2393808A1 (en) 2001-06-21
CN101491536B (zh) 2012-07-04
AU1847901A (en) 2001-06-25
JP4772245B2 (ja) 2011-09-14
EP1238070B1 (en) 2007-08-15
US20070213291A1 (en) 2007-09-13
ATE370231T1 (de) 2007-09-15
NO20022820D0 (no) 2002-06-13
US7157436B2 (en) 2007-01-02
DK1867718T3 (da) 2010-04-12
NO20022820L (no) 2002-08-08
EP1867718A2 (en) 2007-12-19
WO2001044465A3 (en) 2001-11-29
IL150196A0 (en) 2002-12-01
DE60043759D1 (de) 2010-03-11
NO330508B1 (no) 2011-05-09
KR100829646B1 (ko) 2008-05-16
IL150196A (en) 2009-06-15
EP1867718B1 (en) 2010-01-20
PT1238070E (pt) 2007-11-06
CZ20022372A3 (cs) 2002-11-13
CN1433469A (zh) 2003-07-30
US20010041681A1 (en) 2001-11-15
DK1238070T3 (da) 2007-12-03
ATE455851T1 (de) 2010-02-15
JP2003517041A (ja) 2003-05-20
DE60036019D1 (de) 2007-09-27
ES2340807T3 (es) 2010-06-09
KR20020079752A (ko) 2002-10-19
AU785212B2 (en) 2006-11-09
MXPA02005842A (es) 2003-10-14
CN100445380C (zh) 2008-12-24
CN101491536A (zh) 2009-07-29

Similar Documents

Publication Publication Date Title
HUP0300627A2 (hu) Terápiára alkalmas szintetikus oligonukleotidok
GR3024597T3 (en) 7-deazapurine modified oligonucleotides
DE69012141D1 (de) Ortsspezifische modifikation des candida tropicalis genomes.
NO20002113D0 (no) Nye tricykliske forbindelser og deres anvendelse i medisin, fremgangsmÕte for deres fremstillling og farmasøytiske sammensetninger inneholdende dem
FI925174A (fi) Nya organokiselfoereningar och kompositioner innehaollande dem
NO932184D0 (no) Termoherdede beleggsammensetninger med forbedret hardhet
IT230897Y1 (it) Struttura anulare per articoli di gioielleria, oreficeria, bigiotteria o simili, in special modo per anelli.
NO304384B1 (no) Al-Sr-Si-B-forlegering, fremgangsmÕte for dens fremstilling og anvendelse av forlegeringen
DK0567648T3 (da) Afkølingsresistente planter og produktion deraf
IT8883457A0 (it) Impianto di laminazione prodotti piani
IT1239667B (it) Gruppo combinato di raddrizzatura e linearizzazione profilati
ITMI921235A1 (it) Oligonucleotidi antisenso ad attivita' antitumorale, composizioni farmaceutiche che li comprendono, e loro impieghi
NO884324L (no) Fremgangsmaate til fremstilling av reninhemmende dipeptider og deres anvendelse.
DK22391D0 (da) Rekombinant-dna-molekyle og plantetransformationsvektor med overtraeksproteingenet fra agurkemosaikvirus, bakterie- og planteceller indeholdende dem samt saadanne planters produktion
ES472429A1 (es) Un procedimiento para la preparacion de compuestos de 4Ÿ-de-soxi-4-amino-eritromicina a.
IT1236357B (it) Gruppo combinato di raddrizzatura e linearizzazione profilati.
IT8920827A0 (it) Sequenze di nucleotidi.
ITBA910005U1 (it) Serie di appoggi per fornelloni destinati ad uso combinato o singolo.
ITRE930088A1 (it) Impianto ad elevata produttivita' per la fabbricazione di piastrelle ceramiche in genere
ITRM930690A1 (it) Articolo anulare di oreficeria o di bigiotteria, ad elementi componibili.
IT1243467B (it) Ghiera bloccabile di precisione
IT8052950V0 (it) Vasi, portavasi ed elementi decorativi assimilabili aventi sulle pareti esterne incavi ed incisioni oppur unamente modificate, adatte al trapianto di muschi oppur di piccole piante
DK12292D0 (da) Syntese af vigtigt nucleosid, der kan bruges i syntesen af 2',3'-dideoxynucleosider
IT8323593A0 (it) Articolo ceramico di colore oro, duro, decorativo.
IT213906Z2 (it) Microirrigatore di colture di tipo dinamico.

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished